Hepatic Hemangioendothelioma: An update

Table 2 Summaries of chemotherapeutics management studies for hepatic hemangioepithelioma

Study	Year	Country	Patients	Chemotherapy agent	Dose	Outcome	Duration of follow up
Emad et al[55]	2019	Egypt	9/28	Propranolol, prednisolone, vincristine, cyclophos-phamide	First line therapy: 0.6–1.2 mg/kg/d propranolol and/or 0.5-2 mg/kg/d prednisolone	Regression on propranolol, propranolol/prednisolone, propranolol/prednisolone/ vincristine, propranolol/prednisolone/cyclophosphamide, propranolol/prednisolone/vincristine/cyclophosphamide, prednisolone/interferon (1/2)1	Minimum of 12 mo
					Salvage therapy: 1 million units/m2/wk interferon, 1.5 mg/m2/wk vincristine	Progression on prednisolone/interferon (1/2)1, prednisolone/vincristine/cyclophosphamide, Prednisolone/embolization/cyclophosphamide
Kim et al[82]	2010	Japan	1	Carboplatin, paclitaxel, and bevacizumab	15 mg/kg, every 21 d (bevacizumab)	Progression	Not available
Mizota et al[83]	2011	Japan	1	Carboplatin, paclitaxel, and bevacizumab	15 mg/kg, every 21 d (bevacizumab)	Progression	3 mo
Calabro et al[74]	2007	Italy	1	Interferon α-2a	Not available	Stable disease	Not available
Kayler et al[84]	2002	United States	1	Interferon α-2a	3 million units daily	Partial response	4 mo
Marsh R et al[85]	2005	United States	1	Interferon α	3 million units, 5 d/wk for 1 yr	Complete response	84 mo
Galvão et al[50]	2005	Brazil	1	Interferon alpha 2b	3 million units daily 9 weeks before and 1 week after liver resection	Complete response	36 mo
Agulnik et al[64]	2013	United States	1	Bevacizumab	15 mg/kg, every 21 d	Partial response	Not available
Lau et al[63]	2015	United States	1	Capecitabine and bevacizumab	Not available	Partial response	6 mo
Lakkis et al[86]	2013	France	2	Cyclophos-phamide	50 mg daily continuous	Complete response (1/2) and Partial response (1/2)	6 and 24 mo
Sangro et al[87]	2012	Spain	1	Sorafenib	200 mg every 36 hours	Partial response	6 mo
Kobayashi et al[62]	2016	Japan	1	Sorafenib	400-800 mg twice daily	Partial response	60 mo

¹On prednisolone/interferon treatment, regression was reported in 1 patient and progression in the other patient.